Hi-Tech Pharmacal (HITK) Reports Surge in Q1 Sales and EPS
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) reported that first quarter sales rose 175% to $43.48 million and EPS rose to $0.73 from $0.13.
David Seltzer, President and CEO, commented on the results "We are pleased with a record quarter in terms of both sales and earnings. All segments of our business showed growth, led by robust performance of our generic pharmaceuticals. Increased profitability has enabled the Company to stay focused on the aggressive development program for liquid and sterile products where we see multiple opportunities for growth. We are also pleased with the performance of our branded prescription and OTC divisions and keep looking for near and long term licensing opportunities to grow both businesses."
David Seltzer, President and CEO, commented on the results "We are pleased with a record quarter in terms of both sales and earnings. All segments of our business showed growth, led by robust performance of our generic pharmaceuticals. Increased profitability has enabled the Company to stay focused on the aggressive development program for liquid and sterile products where we see multiple opportunities for growth. We are also pleased with the performance of our branded prescription and OTC divisions and keep looking for near and long term licensing opportunities to grow both businesses."
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- VeriFone (PAY) Shares Slammed on Q2 Results, Guidance, Now Down ~9%
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
Create E-mail Alert Related Categories
Earnings, Hot ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
